preface
The 2024 World Lung Cancer Congress (WCLC), organized by the International Association for the Study of Lung Cancer (IASLC), will be held in San Diego, United States, from September 7 to 10 local time. WCLC is a multidisciplinary oncology conference dedicated to lung cancer and other thoracic malignancies, with more than 7,000 professionals from more than 100 countries attending each session to discuss cutting-edge diagnostic and therapeutic advances in lung cancer and other thoracic malignancies.
EGFR is a common driver mutation gene in non-small cell lung cancer (NSCLC), and significant progress has been made in targeted therapy for EGFR mutation-positive to date. So, what new treatment strategies will be unveiled at this year's WCLC? What are the new strategies for dealing with drug resistance after EGFR mutation targeted therapy? At present, the official website discloses the titles of the abstracts selected for this conference (except LBA), and Yimaitong has compiled some relevant studies for readers.
EGFR mutation-targeted therapy
Abstract Number: OA02.03
英文标题：A Phase III Study of Rilertinib Versus Gefitinib as First-Line Therapy for Patients with Locally Advanced or Metastatic EGFR-Mutated NSCLC
Chinese title: A phase III study of reertinib versus gefitinib as first-line treatment in patients with locally advanced or metastatic EGFR-mutant NSCLC
Speaker: Xiong Anwen (Shanghai Pulmonary Hospital)
Abstract Number: OA02.04
英文标题：Lazertinib vs Osimertinib in 1L EGFR-Mutant Advanced NSCLC：A Randomized, Double-Blind, Exploratory Analysis from MARIPOSA
Chinese title: Lazetinib versus osimertinib in first-line treatment of EGFR-positive advanced NSCLC: a randomized, double-blind, exploratory analysis of the MARIPOSA study
讲者：S-H. Lee（三星医疗中心）
Abstract Number: MA12.05
英文标题：PAPILLON：TP53 Co-mutations, Sites of Insertion, and ctDNA Clearance Among Patients with EGFR Ex20ins-Mutated Advanced NSCLC
中文标题：PAPILLON研究：TP53共突变、插入位点及EGFR Ex20ins突变型晚期NSCLC患者的ctDNA清除情况
讲者：J.W. Goldman（David Geffen School of Medicine, University of Californi）
Abstract Number: MA12.06
英文标题：Amivantamab Plus Lazertinib vs Osimertinib in First-Line, EGFR-Mutant Advanced NSCLC：Patient-relevant Outcomes from MARIPOSA
Chinese title: Patient-related outcomes of the MARIPOSA study: amivantamab plus Lazertinib versus osimertinib in the first-line treatment of EGFR-positive advanced NSCLC
讲者：D. Nguyen（City of Hope National Medical Center）
Abstract Number: MA15.11
英文标题：Aumolertinib as Adjuvant Therapy in Resectable I-III EGFR-Mutant NSCLC : Also Effective in Patients with High-Risk Relapse Factors
Chinese title: Adjuvant ametinib in resectable stage I-III EGFR-mutant NSCLC: also effective in patients with high-risk recurrence factors
讲者：J. Yao（吉林省人民医院）
Abstract Number: MA15.12
英文标题：Furmonertinib as Adjuvant Therapy for Completely Resected Stage IA with High-Risk Factors and IB NSCLC Patients with EGFR Mutations
Chinese title: Adjuvant vormetinib in the treatment of patients with stage IA/IB EGFR-mutant NSCLC with high-risk factors who are completely resected
Speaker: R. Geng (Peking Union Medical College Hospital)
摘要号：P1.09C.01
英文标题：A Multicenter, Randomized, Phase II Trial of EGFR TKI with Primary Tumor Resection for EGFR-Mutant Metastatic NSCLC Patients
Chinese title: A multicenter, randomized, phase II trial of EGFR-TKI combined with primary tumor resection in patients with EGFR-mutant metastatic NSCLC
讲者：P-H. Chen（台湾大学附属医院）
摘要号：P1.12A.05
英文标题：Aumolertinib in Treatment-Naïve EGFR-Mutant NSCLC Patients with Brain Metastases:Efficacy and Safety Data from the ARTISTRY
Chinese title: ARTISTRY study: Efficacy and safety of aumolertinib in treatment-naïve patients with EGFR mutation and NSCLC with brain metastases
Speaker: X. Zhang (Henan Provincial Cancer Hospital)
摘要号：P1.12A.07
英文标题：A Phase 1 Study of TY-9591 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients with EGFR Positive Mutation.
Chinese title: A phase I study of TY-9591 in the treatment of EGFR-mutated advanced NSCLC.
Speaker: B. Han (Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine)
摘要号：P3.08F.02
英文标题：MRD Guiding Treatment after Aumolertinib Induction Therapy for EGFRm+ Stage III NSCLC in the MDT Diagnostic Model (APPROACH)
Chinese title: APPROACH study: MRD-guided treatment after EGFR mutation-positive stage III NSCLC after ametinib induction therapy in a diagnostic model of MDT
讲者：S-Y.M. Liu（暨南大学附属第一医院）
摘要号：P3.12D.05
英文标题：Furmonertinib Plus Icotinib as First-Line Treatment in EGFR-Mutated NSCLC: Updated Results in L858R and CNS Metastases Groups
Chinese title: Furmetinib in combination with icotinib as first-line treatment for EGFR-mutant NSCLC: latest results from the L858R mutation and central nervous system metastases group
Speaker: H. Chen (Affiliated Hospital of Guangdong Medical University)
摘要号：P4.07D.02
英文标题：Furmonertinib as Adjuvant Therapy in Postoperative EGFR-Mutated Stage IB-IIA NSCLC with High-Risk Pathological Factors
Chinese title: Fumetinib as an adjuvant therapy for postoperative EGFR-mutant stage IB-IIA NSCLC with high-risk pathological factors
Speaker: X-L. Li (Shanghai First People's Hospital)
摘要号：EP.07C.04
英文标题：Adjuvant Aumolertinib in Resected Stage I EGFR-Mutated NSCLC: Prospectively Evaluating Efficacy in Residual GGN Lesions
Chinese title: Adjuvant ametinib in the treatment of resected stage I EGFR-mutant NSCLC: prospective evaluation of its efficacy in residual pulmonary ground-glass noduular lesions
Speaker: C.B. Huang (Tianjin Cancer Hospital)
摘要号：EP.07C.05
英文标题：Efficacy and Safety of Aumolertinib in Stage IB-IIIA NSCLC after R0 Resection and the Correlation Between Efficacy and Postoperative MRD Status
Chinese title: Efficacy and safety of ametinib in stage IB-IIIA NSCLC after R0 resection and correlation between efficacy and postoperative MRD status
Speaker: S.Yang (Foshan First People's Hospital)
摘要号：EP.07C.13
英文标题：Aumolertinib as Adjuvant Therapy in Postoperative EGFR-Mutated Stage I NSCLC with Multiple High-Risk Factors
Chinese title: Ametinib as adjuvant therapy for EGFR-mutant stage I NSCLC with multiple postoperative risk factors
Speaker: Q.Wu (The First Affiliated Hospital of Xi'an Jiaotong University)
摘要号：EP.07E.04
英文标题：Efficacy and Safety of Anlotinib Plus EGFR-TKIs in Slowly or Locally Progressing NSCLC after Adjuvant Therapy with EGFR-TKIs
Chinese title: Efficacy and safety of anlotinib in combination with EGFR-TKI in NSCLC with slow or local progression after adjuvant EGFR-TKI therapy
Speaker: J. Liu (The First Affiliated Hospital, Zhejiang University School of Medicine)
摘要号：EP.07E.07
英文标题：Adjuvant Aumolertinib in Patients with Completely Resected, Stage IA2-IIIA Non-Small-Cell Lung Cancer with Uncommon EGFR Mutations
Chinese title: Adjuvant ametinib in the treatment of completely resected stage IA2-IIIA NSCLC with rare EGFR mutations
Speaker: H. Ye (The First Affiliated Hospital of Zhejiang University School of Medicine)
摘要号：EP.08F.03
英文标题：Efficacy and Safety of Aumolertinib with Radiotherapy in the Treatment of Unresectable Locally Advanced EGFR-Mutant NSCLC: A Phase II Study
Chinese title: A phase II study of the efficacy and safety of ametinib in combination with radiotherapy in the treatment of unresectable locally advanced EGFR-mutant NSCLC
Speaker: X. MENG (Shandong Provincial Cancer Hospital)
摘要号：EP.09A.03
英文标题：Safety and Efficacyof Cranial Radiotherapy in Combination with Aumolertinibin EGFR-Mutant NSCLC Patients with Brain Metastases
Chinese title: Efficacy and safety of ametinib combined with intracranial radiotherapy in patients with EGFR-mutant NSCLC with brain metastases
Speaker: S. Han (Shenzhen Hospital, Cancer Hospital, Chinese Academy of Medical Sciences)
摘要号：EP.12A.08
英文标题：Furmonertinib as First-Line Therapy for Chinese Patients with EGFR Mutation-positive NSCLC: A Real-World Study
Chinese title: A real-world study of furmetinib in the first-line treatment of Chinese patients with EGFR mutation-positive non-small cell lung cancer
Speaker: N.n. Yan (The First Affiliated Hospital of Zhengzhou University)
摘要号：EP.12A.16
英文标题：High-Dose Aumolertinib Combined Intrathecal Chemotherapy for the Treatment of EGFR-Mutated NSCLC with Leptomeningeal Metastasis
Chinese title: High-dose ametinib combined with intrathecal chemotherapy in EGFR-mutant NSCLC with leptomeningeal metastases
Speaker: W. Wang (Three Gorges Hospital, Chongqing University)
摘要号：EP.12A.20
英文标题：EGFR Inhibitors Combined with Intrathoracic Perfusion Manages Malignant Pleural Effusion in EGFR-Mutated Metastatic Lung Adenocarcinoma
Chinese title: EGFR inhibitor combined with intrathoracic perfusion in the treatment of malignant pleural effusion in EGFR-mutant metastatic lung adenocarcinoma
Speaker: W. Huang (West China Hospital, Sichuan University)
摘要号：EP.12A.22
英文标题：Aumolertinib with Chemotherapy as First-Line Treatment in Patients with EGFR-Mutated Advanced NSCLC: A Real-World Study
Chinese title: A real-world study of ametinib in combination with chemotherapy in the first-line treatment of EGFR-mutated advanced NSCLC
Speaker: J. Xu (The First Affiliated Hospital of Nanjing Medical University)
Strategies to overcome treatment resistance
Abstract Number: MA12.03
英文标题：Vebreltinib Plus PLB1004 In EGFR-Mutated, NSCLC with MET Amplification or MET Overexpression Following EGFR-TKI
Chinese Title: Beritinib in combination with PLB1004 in patients with EGFR-mutant NSCLC with MET amplification or overexpression after EGFR-TKI therapy
Speaker: Li Wei (Shanghai East Hospital)
Abstract Number: MA07.03
英文标题：Systematic Engineering of TROP2 CAR T Cell Therapy to Overcome Resistance Pathways in EGFRmutant NSCLC
Chinese title: Systematically engineering TROP2 CAR T-cell therapy to overcome resistance pathways in EGFR-positive NSCLC
讲者：E.J. Brea（Dana-Farber Cancer Institute）
Abstract Number: MA07.04
英文标题：Targeting CD24 Enhances the Response to Third-Generation Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer
Chinese title: Targeting CD24 enhances the response of EGFR-mutant NSCLC to third-generation TKIs
Speaker: J. Liang (Zhongshan Hospital, Fudan University)
Abstract Number: MA07.06
英文标题：Eradicating Drug Tolerant Persisters (DTPs) In EGFR-Mutated Non Small Cell Lung Cancer (NSCLC) By Targeting TROP2
Chinese title: Eradication of drug-resistant surviving cells (DTPs) in EGFR mutation-positive NSCLC by targeting TROP2
讲者：S. Baldacci（Dana-Farber Cancer Institute）
摘要号：P1.12A.08
英文标题：The Mechanism Study on a Novel CD3-EGFR Bispecific Antibody Combo Improves Osimertinib-Resistant NSCLC Tumor Environment
Chinese title: Mechanism study of novel CD3-EGFR bispecific antibody combinations to improve the tumor environment of osimertinib-resistant NSCLC
Speaker: H. Guo (Shanghai Pulmonary Hospital)
摘要号：EP.12A.21
英文标题：Nimotuzumab Plus Chemotherapy in the Posterior Line Therapy of EGFR-TKIs Resistant Lung Adenocarcinoma: A Case Series Study
Chinese title: Application of nimotuzumab combined with chemotherapy in the posterior treatment of EGFR-TKI-resistant lung adenocarcinoma: a case series
Speaker: K. Lu (Jiangsu Provincial People's Hospital)
摘要号：EP.12A.42
英文标题：Savolitinib Plus Osimertinib in EGFR-Mutant NSCLC with MET Overexpression and Acquired Resistance to Previous EGFR Inhibitor
Chinese title: Savolitinib in combination with osimertinib in the treatment of EGFR-mutant NSCLC with MET overexpression and acquired resistance to previous EGFR inhibitors
Speaker: Y. Mao (Jiangnan University Hospital)
摘要号：EP.12D.04
英文标题：Treatment Pattern and Clinical Outcome in Chinese NSCLC Patients with MET Alterationwho Had Disease Progressionon EGFR-TKIs
Chinese title: Treatment patterns and clinical outcomes in Chinese patients with MET-mutant NSCLC with disease progression after EGFR-TKI therapy
Speaker: X. Wang (Jiangnan University Hospital)
Note: Rankings are in no particular order, in order of abstract number.
If you have any omissions or any questions, please leave us a message~ Please pay attention to Yimaitong thoracic tumor!
Source: WCLC official website
Typography: Squid
Execution: Squid
Yimaitong is a professional online doctor platform, and the mission of the platform is to "sense the pulse of the world's medicine and help China's clinical decision-making". Yimaitong has a series of products such as "Clinical Guidelines", "Medication Reference", "Medical Literature King", "Yizhiyuan", "eYantong" and "ePulse", which fully meet the needs of medical workers in clinical decision-making, obtaining new knowledge and improving scientific research efficiency.
This platform aims to deliver more medical information to healthcare professionals. The content published on this platform should not be used as a substitute for professional medical guidance in any way, nor should it be regarded as diagnosis and treatment advice. If such information is used for purposes other than understanding medical information, the platform does not assume relevant responsibilities. This platform does not mean that it agrees with its descriptions and views on the published content. If copyright issues are involved, please contact us, and we will deal with it as soon as possible.